• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Canopy Growth Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8/29/25 5:03:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CGC alert in real time by email
    false 0001737927 Canopy Growth Corp 00-0000000 0001737927 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): August 29, 2025

     

     

     

    Canopy Growth Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Canada   001-38496   N/A
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    1 Hershey Drive
    Smiths Falls, Ontario
    K7A 0A8
    (Address of principal executive offices) (Zip Code)

     

    (855) 558-9333

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading
    Symbol(s)
    Name of each exchange
    on which registered
    Common Shares, no par value CGC Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company    ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

     

    Item 7.01.Regulation FD Disclosure.

     

    On August 29, 2025, Canopy Growth Corporation (the “Company”) issued a press release announcing its new at-the-market equity program, which is attached as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

     

    The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any incorporation by reference language in any such filing.

     

    Item 8.01.Other Events.

     

    On August 29, 2025, the Company entered into an equity distribution agreement (the “Equity Distribution Agreement”) with BMO Capital Markets Corp. (the “U.S. Agent”) and BMO Nesbitt Burns Inc. (the “Canadian Agent”, and together with the U.S. Agent, the “Agents” and each an “Agent”), pursuant to which the Company may offer and sell, from time to time, up to an aggregate offering price of up to $200,000,000 of the Company’s common shares (the “Common Shares”) through the U.S. Agent, less any amounts sold in Canada through the Canadian Agent pursuant to the Concurrent Canadian Offering (as defined below); provided, however, that (i) in no event will the Company sell Common Shares in the Concurrent Canadian Offering for aggregate gross sales proceeds exceeding $50,000,000 (the “Canadian Cap”) and (ii) in no event will the combined gross sales proceeds of the U.S. Offering (as defined below) and the Concurrent Canadian Offering exceed $200,000,000. The U.S. Agent may sell Common Shares only in the United States (the “U.S. Offering”), and the Canadian Agent may sell Common Shares only on marketplaces in Canada (the “Concurrent Canadian Offering”), subject to the Canadian Cap. The Equity Distribution Agreement replaces the equity distribution agreement, dated February 28, 2025, as amended, among the Company and the Agents, which terminated upon the Company’s entry into the Equity Distribution Agreement.

     

    In the U.S. Offering, sales of Common Shares, if any, will be made by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act, including, but not limited to, sales made directly on The Nasdaq Global Select Market or any other trading market for the Common Shares in the United States or pursuant to any other sales method used by the U.S. Agent. In the Concurrent Canadian Offering, sales of Common Shares, if any, will be made in transactions that are deemed to be “at-the-market distributions” as defined in National Instrument 44-102 — Shelf Distributions, including sales made by the Canadian Agent directly on the Toronto Stock Exchange or any other marketplace for the Common Shares in Canada or pursuant to any other sales method used by the Canadian Agent. The Agents may also sell the Common Shares by any other method agreed by the Company and the applicable Agent and permitted by applicable law, including, without limitation, as block transactions. Actual sales of Common Shares pursuant to the Equity Distribution Agreement will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Common Shares, capital needs and determinations by the Company of the appropriate sources of funding for the Company.

     

    Subject to the terms and conditions of the Equity Distribution Agreement, the Agents will use their commercially reasonable efforts to sell the Common Shares from time to time, as sales agents, based upon the Company’s instructions.

     

    The Company has no obligation to sell any of the Common Shares and may at any time suspend offers under the Equity Distribution Agreement, and either the Company or the Agents may terminate the Equity Distribution Agreement at any time. The Equity Distribution Agreement contains customary representations, warranties and covenants of the Company, indemnification rights and obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Equity Distribution Agreement were made only for purposes of the Equity Distribution Agreement and as of specific dates, were solely for the benefit of the parties to the Equity Distribution Agreement and are subject to certain limitations contained in the Equity Distribution Agreement. Accordingly, investors and security holders should not rely on the representations and warranties in the Equity Distribution Agreement as characterizations of the actual state of facts.

     

     

     

     

    The U.S. Offering is being made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279949), filed with the Securities and Exchange Commission (the “SEC”) on June 5, 2024, and amended on May 29, 2025 and May 30, 2025 (as amended, the “Registration Statement”), a base prospectus, dated June 4, 2025, included as part of the Registration Statement, and a prospectus supplement, dated August 29, 2025 filed with the SEC pursuant to Rule 424(b)(5) on August 29, 2025. The Concurrent Canadian Offering is being made pursuant to a preliminary short form base shelf prospectus dated May 14, 2024, a (final) short form base shelf prospectus dated June 5, 2024 and a prospectus supplement dated August 29, 2025, filed with the securities commissions or similar authorities in each of the provinces and territories of Canada.

     

    This Current Report shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares nor shall there be any sale of the Common Shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

     

    The foregoing description of the Equity Distribution Agreement is not complete and is qualified in its entirety by reference to the full text of the Equity Distribution Agreement, a copy of which is attached as Exhibit 1.1 to this Current Report and is incorporated by reference herein.

     

    The legal opinion of Cassels Brock & Blackwell LLP relating to the Common Shares being offered pursuant to the Equity Distribution Agreement is filed as Exhibit 5.1 to this Current Report.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Exhibit Description
    1.1*+   Equity Distribution Agreement, dated as of August 29, 2025, by and among Canopy Growth Corporation and BMO Capital Markets Corp. and BMO Nesbitt Burns Inc.
    5.1   Opinion of Cassels Brock & Blackwell LLP
    23.1   Consent of Cassels Brock & Blackwell LLP (included in Exhibit 5.1)
    99.1   Press Release, dated August 29, 2025
    104   Cover Page Interactive Data File (formatted in Inline XBRL document)

     

    *A non-material exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of the omitted exhibit upon request by the SEC.
    +Portions of this exhibit have been omitted pursuant to Item 601(a)(6) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

      CANOPY GROWTH CORPORATION
         
    Date: August 29, 2025 By: /s/ Thomas Stewart
        Thomas Stewart
        Interim Chief Financial Officer

     

     

    Get the next $CGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGC

    DatePrice TargetRatingAnalyst
    4/4/2023Underperform → Mkt Perform
    Bernstein
    11/2/2022$1.50Underperform
    Bernstein
    10/26/2022Sell → Hold
    Canaccord Genuity
    6/8/2022Market Perform → Underperform
    BMO Capital Markets
    3/22/2022Equal Weight → Underweight
    Barclays
    3/1/2022$14.00 → $9.00Equal-Weight
    Barclays
    2/18/2022$9.60 → $11.00Neutral
    Cantor Fitzgerald
    12/22/2021Neutral → Underperform
    BofA Securities
    More analyst ratings

    $CGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Stewart Thomas Carlton sold $10,036 worth of shares (5,768 units at $1.74), decreasing direct ownership by 8% to 68,203 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    8/26/25 4:15:57 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Gedeon Christelle sold $29,456 worth of shares (16,929 units at $1.74), decreasing direct ownership by 4% to 368,488 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    8/26/25 4:15:17 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Gedeon Christelle sold $8,422 worth of shares (4,528 units at $1.86), decreasing direct ownership by 1% to 385,417 units (SEC Form 4)

    4 - Canopy Growth Corp (0001737927) (Issuer)

    8/20/25 4:30:19 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Canopy Growth Establishes New US$200 Million At-The-Market Program to Strengthen the Company's Financial Position

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that the Company has established a new at-the-market equity program (the "ATM Program") that allows Canopy Growth to issue and sell up to US$200 million of common shares of the Company ("Common Shares") from treasury from time to time in concurrent public offerings in the United States (the "U.S. Offering") and Canada; provided, however, that (i) sales of Common Shares in the ATM Program in Canada is limited to aggregate gross sales proceeds to the Company of up to US$50 million (or its Canadian

    8/29/25 4:55:00 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Welcomes Cannabis Veteran Eric Ruhle as New Vice President of Brand Sales

    BOULDER, Colo., Aug. 27, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the U.S. cannabis market, today announced the appointment of Eric Ruhle as Vice President of Brand Sales, overseeing sales strategy across the full Canopy USA portfolio. With more than 11 years of experience in the regulated cannabis industry, Ruhle brings deep expertise in building and leading high-performing sales organizations. Most recently, he served as Senior Regional Sales Manager at Kiva Sales & Services, where he navigated the highl

    8/27/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

    New leaders will be responsible for driving portfolio growth, operational improvements, and market expansion BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. cannabis market, today announced the appointment of a new executive team responsible for driving the Company's next phase of expansion. Drawing on extensive industry experience, these leaders will steer Canopy USA forward through a shared vision to elevate the compa

    8/18/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    SEC Filings

    View All

    Canopy Growth Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Canopy Growth Corp (0001737927) (Filer)

    8/29/25 5:03:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Canopy Growth Corporation

    424B5 - Canopy Growth Corp (0001737927) (Filer)

    8/29/25 4:12:22 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Canopy Growth Corporation

    DEFA14A - Canopy Growth Corp (0001737927) (Filer)

    8/19/25 4:15:55 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canopy Growth upgraded by Bernstein

    Bernstein upgraded Canopy Growth from Underperform to Mkt Perform

    4/4/23 9:09:41 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Canopy Growth with a new price target

    Bernstein initiated coverage of Canopy Growth with a rating of Underperform and set a new price target of $1.50

    11/2/22 6:11:10 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Canopy Growth from Sell to Hold

    10/26/22 7:36:52 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Financials

    Live finance-specific insights

    View All

    Canopy Growth Reports First Quarter Fiscal 2026 Financial Results; Cannabis Revenue Increased 24% Year-Over-Year

     Canada adult-use cannabis Q1 FY2026 net revenue increased 43% year-over-year, benefiting from increased distribution and strong consumer demand for new products, including Claybourne infused pre-roll joints Company has achieved $17MM of planned $20MM annualized savings target since March 1, 2025; SG&A expenses down 21% year-over-year in Q1 FY2026 compared to Q1 FY2025 Supply chain improvements in international markets expected to increase cannabis supply and consistency in margin accretive European markets in the second half of FY2026 Company expects to launch a new Storz & Bickel vaporizer during the second half of the calendar year Canopy Growth Corporation ("Canopy Growth" or th

    8/8/25 7:00:00 AM ET
    $CGC
    $DRI
    Medicinal Chemicals and Botanical Products
    Health Care
    Restaurants
    Consumer Discretionary

    Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025

    Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: https://onlinexperiences.com/Launch/QReg/ShowUUID=8135284A-F8CD-45B7-A384-634DE6714986 Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at:

    7/25/25 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Reports Fourth Quarter and Fiscal Year 2025 Financial Results

    Canada cannabis revenue increased 4% in Q4 FY2025 year-over-year, led by 13% growth in Canada medical cannabis Reduced total debt by $293 million or 49% during FY2025 Refined strategy, focus and organizational structure expected to accelerate growth in global medical cannabis and improve commercial execution in Canada adult-use cannabis Additional cost reduction initiatives identified and initiated in Q4 FY2025 are expected to deliver at least $20 million in annualized savings over the next 12-18 months Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced its financial results for the fourth quarter ended March 31, 2025 ("Q4 FY2025") a

    5/30/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    4/19/24 5:00:49 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    11/3/23 4:30:53 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Canopy Growth Corporation (Amendment)

    SC 13D/A - Canopy Growth Corp (0001737927) (Subject)

    7/20/23 4:35:52 PM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    $CGC
    Leadership Updates

    Live Leadership Updates

    View All

    Canopy USA Welcomes Cannabis Veteran Eric Ruhle as New Vice President of Brand Sales

    BOULDER, Colo., Aug. 27, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the U.S. cannabis market, today announced the appointment of Eric Ruhle as Vice President of Brand Sales, overseeing sales strategy across the full Canopy USA portfolio. With more than 11 years of experience in the regulated cannabis industry, Ruhle brings deep expertise in building and leading high-performing sales organizations. Most recently, he served as Senior Regional Sales Manager at Kiva Sales & Services, where he navigated the highl

    8/27/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy USA Appoints New Executive Team to Accelerate Growth Across U.S. Cannabis Market

    New leaders will be responsible for driving portfolio growth, operational improvements, and market expansion BOULDER, Colo., Aug. 18, 2025 /PRNewswire/ -- Canopy USA, LLC ("Canopy USA"), a brand-driven organization strategically positioned across the fastest growing states and highest potential segments of the U.S. cannabis market, today announced the appointment of a new executive team responsible for driving the Company's next phase of expansion. Drawing on extensive industry experience, these leaders will steer Canopy USA forward through a shared vision to elevate the compa

    8/18/25 8:01:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    Canopy Growth Announces Mailing and Filing of Proxy Materials for Annual General and Special Meeting and Urges All Shareholders to Vote Now

    Voting is important and easy; shareholders are urged to vote today to help the Company avoid incurring additional costs. Canopy Growth shareholders with a 16-digit control number can vote online at http://proxyvote.com, and by phone at 1-800-474-7493. For more information, shareholders should contact Canopy Growth's strategic shareholder advisor and proxy solicitation agent, Laurel Hill Advisory Group, at 1-877-452-7184 (1‑416‑304‑0211 for collect calls outside North America) or by email at [email protected]. Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED, NASDAQ:CGC) announced today that the Company has mailed (or mailed a notice of internet availa

    8/15/25 7:00:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care